Tilray Brands, Inc. Common Stock (TLRY) Stock
Key stats
- Market cap
- $474.40M
- Price / Earnings ratio
- -2.8x
- EPS (TTM)
- -$1.41
- Volume
- Loading
- 52-week high
- $15.70
- 52-week low
- $0.77
- EPS vs analyst estimate
- +100.0%Q1 FY26 · $0.00 vs -$0.01
Source: third-party data provider, as of October 17, 2026
EPS estimate: analyst consensus
Compare with TLRY
Recent news

Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026?
Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026?
TLRY

3 Huge Red Flags From Tilray's Q1 Earnings Report
3 Huge Red Flags From Tilray's Q1 Earnings Report
TLRY

Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026?
Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026?
TLRY

3 Reasons I'm Still Not Buying Tilray Stock -- Even at Penny-Stock Prices
3 Reasons I'm Still Not Buying Tilray Stock -- Even at Penny-Stock Prices
TLRY
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 28.02
- MACD 12/26/9
- -0.26
- EMA 9 of MACD
- -0.21
- MACD histogram
- -0.05
- SMA 50
- $4.18
- Price below SMA 50
- EMA 50
- $4.04
- Price below EMA 50
- SMA 200
- $5.83
- Price below SMA 200
- EMA 200
- $6.24
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2026Earnings
The market is expecting earnings per share of -$0.02 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026?
Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026?
TLRY

3 Huge Red Flags From Tilray's Q1 Earnings Report
3 Huge Red Flags From Tilray's Q1 Earnings Report
TLRY

Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026?
Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026?
TLRY

3 Reasons I'm Still Not Buying Tilray Stock -- Even at Penny-Stock Prices
3 Reasons I'm Still Not Buying Tilray Stock -- Even at Penny-Stock Prices
TLRY

Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
TLRY

Tilray Brands Q1 Earnings Call Highlights
Tilray Brands Q1 Earnings Call Highlights
TLRY

Tilray revenue rises as beverage business drives record quarterly sales
Tilray revenue rises as beverage business drives record quarterly sales
TLRY

Tilray Brands Sinks 4% as Record Revenue Masks Shrinking Cannabis Sales; Canopy Growth and Aurora Cannabis Ease
Tilray Brands Sinks 4% as Record Revenue Masks Shrinking Cannabis Sales; Canopy Growth and Aurora Cannabis Ease
TLRY

Tilray Brands, Inc. (TLRY) Reports Q1 Loss, Misses Revenue Estimates
Tilray Brands, Inc. (TLRY) Reports Q1 Loss, Misses Revenue Estimates
TLRY

Curaleaf's Higher Aurora Bid Raises the Stakes in Cannabis Consolidation
Curaleaf's Higher Aurora Bid Raises the Stakes in Cannabis Consolidation
TLRY
News tone: automated (AI) classification of the article's content, not a price prediction.
About Tilray Brands, Inc. Common Stock
Tilray is a global pioneer in the research, cultivation, production and distribution of medical cannabis and cannabinoids. Tilray was the first licensed producer of medical cannabis in the world to have its facility Good Manufacturing Practices (GMP) certified in accordance with European Medicine Agency (EMA) standards.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Irwin David Simon | President, CEO & Chairman | 1958 |
| Mr. Carl A. Merton CA, CBV, CPA | CFO & Principal Accounting Officer | 1970 |
| Mr. Mitchell S. Gendel J.D. | Global General Counsel & Corporate Secretary | 1966 |
| Ms. Denise Menikheim Faltischek | Chief Strategy Officer and Head of M&A | 1973 |
| Mr. Lloyd Brathwaite | Chief Information Officer | — |
| Ms. Nyree Pinto | Chief Human Resources Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 17, 2026
Technical indicators
- RSI 14
- 28.02
- MACD 12/26/9
- -0.26
- EMA 9 of MACD
- -0.21
- MACD histogram
- -0.05
- SMA 50
- $4.18
- Price below SMA 50
- EMA 50
- $4.04
- Price below EMA 50
- SMA 200
- $5.83
- Price below SMA 200
- EMA 200
- $6.24
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +2.3 | -5.9 | -24.2 | |||||||||
| 2022 | -19.4 | -1.9 | +32.8 | -33.4 | -14.1 | -25.4 | +15.9 | +11.1 | -23.2 | +41.8 | +1.3 | -35.5 |
| 2023 | +17.8 | -15.0 | -8.0 | -7.5 | -26.8 | -8.2 | +49.7 | +24.4 | -20.1 | -20.7 | +4.6 | +21.1 |
| 2024 | -17.6 | -11.7 | +42.8 | +1.6 | -10.9 | -7.5 | +20.8 | -14.1 | +4.8 | -2.4 | -18.3 | -0.7 |
| 2025 | -28.1 | -25.8 | -3.7 | -25.8 | -12.3 | +1.7 | +37.7 | +142.5 | +38.4 | -19.0 | -37.9 | +15.5 |
| 2026 | -23.3 | +5.8 | -14.9 | +1.6 | -10.6 | -18.2 | +2.5 | -1.5 | -16.7 | -10.1 |



